rxlist.com (Anectine ) Keywords Reversible Denervation Agent Ganglionic Blocker Mecamylamine Trade Names: Mecamylamine (Vecamyl ) Drug Class: Ganglionic blocker Mechanism of Action: Selectively blocks the open pore of the ganglionic subtype of nicotinic receptor/channel complex by a non-competitive mechanism
Outcome 00:14:31 Meta-analysis, Methods, Evidence Quality 00:22:45 Evidence Hierarchy, Randomized Controlled Trials, Cohort Data 00:33:53 Sponsor: AG1 00:35:05 Dont Turn Your Brain Off
Dark spots on the face are one of the most common skin concerns among people in India, especially in cities like Hyderabad, Bangalore, and Mumbai where heat, humidity, and pollution take a daily toll on skin
A method for monitoring the effect of an adrenoleukodystrophy therapy in a subject suffering from adrenoleukodystrophy comprising determining in a sample from said subject a value selected from the group consisting of- the levels of sphingosine-1-phosphate,- the expression levels of sphingosine-2-phopshate kinase,- the expression levels sphingosine-1-phosphate receptor,- the expression levels of adiponectin,- the levels of at least one marker as defined in Table 1,- the levels of at least one marker as defined in Table 2,- the levels of at least one marker as defined in Table 3,- the levels of at least one marker as defined in Table 4,- the expression levels of at least one marker as defined in Table 5,- the levels of at least one marker as defined in Table 6,- the expression levels of at least one marker as defined in Table 7 and- the expression levels of at least one marker as defined in Table 8 wherein increased levels of sphingosine-1-phosphate, increased levels of sphingosine-2-phopshate kinase, increased levels of sphingosine-1-phosphate receptor, decreased expression levels of adiponectin, increased levels of at least one marker as defined in Table 1, decreased levels of at least one marker as defined in Table 2, increased levels of at least one marker as defined in Table 3, decreased levels of at least one marker as defined in Table 4, increased expression levels of at least one marker as defined in Table 5, increased levels of at least one marker as defined in Table 6, increased expression levels of at least one marker as defined in Table 7, and/or increased expression levels of at least one marker as defined in Table 8 with respect to the value determined prior to the administration of the therapy is indicative that the therapy is not effective or wherein decreased levels of sphingosine-1-phosphate, decreased levels of sphingosine-2-phopshate kinase, decreased levels of sphingosine-1-phosphate receptor, increased expression levels of adiponectin, decreased levels of at least one marker as defined in Table 1, increased levels of at least one marker as defined in Table 2, decreased levels of at least one marker as defined in Table 3, increased levels of at least one marker as defined in Table 4, decreased expression levels of at least one marker as defined in Table 5, decreased levels of at least one marker as defined in Table 6, decreased expression levels of at least one marker as defined in Table 7, and/or decreased expression levels of at least one marker as defined in Table 8 with respect to a value determined prior to the administration of the therapy is indicative that the therapy is effective
doi: 10.1038/bjc.2015.153
